Category Archives: Cardiovascular

<div data-thumb="https://scx1.b-cdn.net/csz/news/tmb/2023/new-instrument-for-pre.jpg" data-src="https://scx2.b-cdn.net/gfx/news/hires/2023/new-instrument-for-pre.jpg" data-sub-html="Antigen standard curves for four of the assays in the CVD-21 panel. Antigen standard curves were generated for all 21 assays and analyzed in multiplex. The figure shows the standard curves for IL-6, TRAIL-R2, U-PAR, and NT-proBNP. Data were normalized against an internal control assay and calibrators, and curve-fitting was performed using […]

Lung cancer survival rates are on the rise 51 mins ago .cls-3{fill:#fff;fill-rule:evenodd} Sitting can cause problems to cardiovascular health … 1 hour ago .cls-3{fill:#fff;fill-rule:evenodd} Hiring Happening Now for Holiday Workers 1 hour ago .cls-3{fill:#fff;fill-rule:evenodd} PECAN OR PE-CAN? 1 hour ago .cls-3{fill:#fff;fill-rule:evenodd} The PHL17 family is growing! Kelsey is having a baby 20 hours ago .cls-3{fill:#fff;fill-rule:evenodd} Is […]

image:  Agneta Siegbahn, Professor of Clinical Coagulation Science at the Department of Medical Sciences, Uppsala University, Sweden. view more  Credit: Hans Siegbahn Researchers at Uppsala University have developed an instrument that makes it possible to measure 21 biomarkers for cardiovascular disease simultaneously with great precision by means of a simple blood test. The aim is […]

Newswise — New research finds the newly popular GLP-1 drug, semaglutide (used in therapies like Ozempic and Wegovy) is tied to a 20% reduction in cardiovascular events for overweight or obese adults who don’t have diabetes. The finding is being called a game-changer by Nishant Shah, M.D., a Duke Health cardiologist with expertise in cardiovascular […]

Semaglutide (brand name: Wegovy®) has the potential to markedly reduce the risk of heart attacks and other heart-related conditions among millions of Americans people with obesity who have also been diagnosed with cardiovascular disease, a Yale study shows. The population that can benefit from the application of the SELECT trial results is growing, indicating the […]

Specialty

Nov. 15, 2023 – Did the pandemic throw your work schedule upside down? If you now have any more flexibility in how and when you do your work, there’s good news: Researchers have found a compelling link between a flexible workplace and a reduced risk of diseases of your heart and blood vessels.  Epidemiologist Lisa […]

Originally developed to treat diabetes, semaglutide is now famous for its weight-loss properties. New research points to yet another potential benefit – boosting heart health. Manufacturer of semaglutide drugs Wegovy and Ozempic – Novo Nordisk – funded a study of 17,604 people that suggests semaglutide can lower the risk of heart-related deaths in certain cohorts […]